Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia - Full Text View

Purpose

To evaluate the safety and efficacy profile of different treatment regimens of INCB018424 administered to two groups of patients; those with polycythemia vera (PV) and those with essential thrombocythemia (ET). Patients in each group will be refractory to hydroxyurea or for whom hydroxyurea is contraindicated.

Condition	Intervention	Phase
Polycythemia Vera Essential Thrombocythemia	Drug: INCB018424	Phase II

Genetics Home Reference related topics:

hemophilia

Drug Information available for:

Hydroxyurea

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study

Official Title:	An Open-Label Study to Determine the Safety and Efficacy of INCB018424 in Patients With Advanced Polycythemia Vera or Essential Thrombocythemia Refractory to Hydroxyurea

Further study details as provided by Incyte Corporation:

Primary Outcome Measures:

Hematological response [ Time Frame: Individual timepoints sustained for at least 2 months ] [ Designated as safety issue: No ]
Symptomatic response [ Time Frame: Individual timepoints sustained for at least 2 months ] [ Designated as safety issue: No ]
Splenomegaly response [ Time Frame: Individual timepoints sustained for at least 2 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Change in PD markers (e.g. plasma cytokines) [ Time Frame: End of Study ] [ Designated as safety issue: No ]
Safety and tolerability assessed by monitoring adverse events [ Time Frame: Ongoing and end of study ] [ Designated as safety issue: Yes ]

Estimated Enrollment:	105
Study Start Date:	July 2008
Estimated Primary Completion Date:	June 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental	Drug: INCB018424 Treatment Arm 1 - 10mg BID
2: Experimental	Drug: INCB018424 Treatment Arm 2 - 25mg BID
3: Experimental	Drug: INCB018424 Treatment Arm 3 - 50mg QD

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Confirmed diagnosis of polycythemia vera or essential thrombocythemia as determined by treating physician
Disease refractory to hydroxyurea or for whom treatment with hydroxyurea is contraindicated or have refused further treatment with hydroxyurea due to side effects.
Patient meets baseline clinical lab parameters

Exclusion Criteria:

Treatment with interferon alpha or anagrelide within 7 days and hydroxyurea within 1 day of starting INCB018424.
Patients diagnosed with another malignancy unless the malignancy was cervical intraepithelial neoplasia or basal or squamous cell skin cancer and the patient has been disease free for > 3 years
Patients receiving therapy with intermediate or high dose steroids greater than the equivalent of 10 mg prednisone per day
Clinically significant cardiac disease (NYHA Class III or IV)

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00726232

Contacts


Contact: William Garrett, MBA	302-498-6987	wgarrett@incyte.com

Locations


United States, Texas
		Recruiting
	Houston, Texas, United States, 77030

Sponsors and Collaborators

Incyte Corporation

Investigators


Study Director:	Edward Bradley, MD	Incyte Corporation

More Information

Responsible Party:	Incyte Corporation ( Pamela Murphy, VP Communications & IR )
Study ID Numbers:	INCB 18424-256
First Received:	July 29, 2008
Last Updated:	July 30, 2008
ClinicalTrials.gov Identifier:	NCT00726232
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Polycythemia

Polycythemia Vera

Essential thrombocytosis

Hydroxyurea

Hematologic Diseases

Blood Coagulation Disorders

Blood Platelet Disorders

Myeloproliferative Disorders

Polycythemia vera

Hemostatic Disorders

Thrombocytopathy

Hemorrhagic Disorders

Hemorrhagic thrombocythemia

Thrombocytosis

Thrombocythemia, Hemorrhagic

Bone Marrow Diseases

ClinicalTrials.gov processed this record on November 30, 2008

Sponsored by:	Incyte Corporation
Information provided by:	Incyte Corporation
ClinicalTrials.gov Identifier:	NCT00726232